135 results
8-K
EX-99.2
AVXL
Anavex Life Sciences Corporation
7 Feb 07
Anavex Life Sciences Corp. acquires a portfolio of Patents and appoints Dr. Alexandre Vamvakides as CSO and Director
12:00am
programs have helped build a strong pipeline that targets a range of serious neurological diseases, including Alzheimer’s Disease (AD), Epilepsy …
Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer
8-K
EX-99.1
AVXL
Anavex Life Sciences Corporation
22 Feb 07
Entry into a Material Definitive Agreement
12:00am
tumors.
The Company's innovative drug discovery and development programs have helped build a strong pipeline that targets a wide range of solid … . is a biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases utilizing a fairly new
8-K
EX-99.1
AVXL
Anavex Life Sciences Corporation
15 Oct 20
Regulation FD Disclosure
7:02am
Advances in Experimental Medicine and Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets.
3 Source: www.alz.org … ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising
8-K
EX-99.1
AVXL
Anavex Life Sciences Corporation
6 Nov 20
Other Events
11:15am
964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets.
7 Source: https://www.alz.org/alzheimers-dementia/what-is-dementia/types … to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising
8-K
EX-99.1
AVXL
Anavex Life Sciences Corporation
21 Oct 11
Anavex Announces Resignation of Director
12:00am
high affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated anti-amnesic
8-K
EX-99.1
ikm8jwq
2 Dec 22
Other Events
8:13am
8-K
EX-99.1
b4hn3
15 Dec 20
Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I
7:06am
8-K
EX-99.1
g5qj5dqu93av4jtj e86
28 Mar 12
Anavex announces director resignation
12:00am
8-K
EX-99.1
rmu4kx3wv6k7czjyfdj
13 Feb 12
Anavex Closes Private Placement
12:00am
8-K
EX-99.2
dthpsm81iy1vspget
28 Feb 11
Anavex Appoints DR. Rachelle Doody to Scientific Advisory Board
12:00am
8-K
EX-99.1
2bgfcpvsjn606dpe
9 Feb 07
Departure of Directors or Principal Officers
12:00am
8-K
EX-99.1
9591qjv
8 Dec 11
Anavex Closes Private Placement
12:00am
8-K
EX-99.1
xv18du
21 Sep 11
Anavex announces director resignation
12:00am
8-K
EX-99.1
jxollfvzq or
4 May 10
Anavex Announces Results of Annual Meeting
12:00am
8-K
EX-99.1
fins0
30 Nov 10
Anavex Announces Private Placement
12:00am
8-K/A
EX-99.1
f90kuod
10 May 11
Unregistered Sales of Equity Securities
12:00am
8-K
EX-99.2
y8qvh78ktzoqz6
3 Aug 11
Other Events
12:00am
8-K
3eqm f6wddut
7 Feb 07
Anavex Life Sciences Corp. acquires a portfolio of Patents and appoints Dr. Alexandre Vamvakides as CSO and Director
12:00am
8-K/A
EX-99.1
0hx0cx83d9p4x
7 Oct 15
Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
12:00am
8-K
EX-99.1
c1hsmww2w4qjvggfmmz
12 Dec 14
Other Events
12:00am